Neurizon Therapeutics Limited has released a press release.
Epichem enters voluntary liquidation
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- MND Trial Successfully Completes 3rd Patient Cohort
- Canine Trial Update
- Results show MPL suppresses biomarkers associated with MND
- Louie the Beagle surpasses one year on MPL
- MND Biomarkers and Pharmacodynamics Results
Later from Neurizon Therapeutics
- Cohort 3 Pharmacokinetics in MND Patients Completed
- Additional Phase 1 data suggest MPL may inhibit MND
- Chief Executive Officer Appointment
- Appendix 4E & Full Year Statutory Accounts
- Canine Oncology Data Supports Progression to Registration
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics